Search
News & Events
Urgent action needed to stop 500 preventable deathsA new report predicts rheumatic heart disease (RHD) will lead to over 500 preventable deaths and cost the Australian health system $317 million by 2031 if no further action to tackle the disease is taken.
News & Events
Bupa pledges half a million dollars to end rheumatic heart diseaseResearchers will extend a unique community-led project to end rheumatic heart disease in Aboriginal communities, thanks to nearly half a million dollars in funding from Bupa.
News & Events
The Kids Research Institute Australia researcher wins Eureka Prize for Emerging Leader in SciencePaediatric infectious disease expert and clinician-scientist Associate Professor Asha Bowen has been named as the Emerging Leader in Science at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.
News & Events
World-first nasal spray whooping cough vaccine aims to protect young bubsTiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.
Prevention of respiratory syncytial virus (RSV) is now a real possibility thanks to the rollout of an immunisation program backed by a decade’s worth of epidemiological research led by The Kids Research Institute Australia.
The Kids Research Institute Australia is playing a key role within a global team of experts whose work is transforming efforts to tackle a potentially deadly disease that disproportionately affects Aboriginal and Torres Strait Islander children in remote Australia.
People
Dr Charlie McLeodDr Charlie McLeod is a Deputy Head at the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, and of a member of the Centre's Infectious Diseases Implementation Research (IDIR) team.
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
News & Events
Program aims to stop skin infections in their tracksAn innovative program set to run for about two and a half years aims to halve the number of children affected by skin infections.
News & Events
Cholesterol and blood pressure drugs help teens with diabetesThe study involved screening young people to learn more about the development of long-term kidney, eye and cardiovascular complications in adolescents with T1D.